A randomized multicenter trial to assess the efficacy of a combined therapy with Sirolimus (Rapamune [RM]), MMF (Cellcept [RM]) and corticosteroids after early elimination of cyclosporin compared to a standard immunosuppressant with cyclosporin, MMF and corticosteroids in patients after kidney transplantation

Trial Profile

A randomized multicenter trial to assess the efficacy of a combined therapy with Sirolimus (Rapamune [RM]), MMF (Cellcept [RM]) and corticosteroids after early elimination of cyclosporin compared to a standard immunosuppressant with cyclosporin, MMF and corticosteroids in patients after kidney transplantation

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Sep 2011

At a glance

  • Drugs Sirolimus (Primary) ; Antithymocyte globulin; Ciclosporin; Corticosteroids; Methylprednisolone; Mycophenolate mofetil
  • Indications Renal transplant rejection
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SMART
  • Most Recent Events

    • 07 Sep 2011 Two- and 3-year follow-up data presented at the 15th Congress of the European Society for Organ Transplantation.
    • 11 May 2010 Results published in Transplantation.
    • 30 Aug 2009 Results were presented at the 14th Congress of the European Society for Organ Transplantation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top